Should I buy or sell Genmab A/S stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 3 sell ratings, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares. View GMAB analyst ratings or view top-rated stocks .

What is Genmab A/S's stock price target for 2024?

13 brokerages have issued 12 month price targets for Genmab A/S's stock. Their GMAB share price targets range from $46.00 to $50.00. On average, they anticipate the company's share price to reach $48.50 in the next twelve months. This suggests a possible upside of 64.2% from the stock's current price. View analysts price targets for GMAB or view top-rated stocks among Wall Street analysts .

How have GMAB shares performed in 2024?

Genmab A/S's stock was trading at $31.84 at the beginning of 2024. Since then, GMAB stock has decreased by 7.2% and is now trading at $29.54. View the best growth stocks for 2024 here .

Are investors shorting Genmab A/S?

Genmab A/S saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,400,000 shares, an increase of 17.1% from the March 15th total of 2,050,000 shares. Based on an average daily volume of 626,600 shares, the short-interest ratio is currently 3.8 days. Approximately 0.4% of the company's stock are short sold. View Genmab A/S's Short Interest .

When is Genmab A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our GMAB earnings forecast .

How were Genmab A/S's earnings last quarter?

Genmab A/S (NASDAQ:GMAB) issued its quarterly earnings data on Wednesday, February, 14th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.02. The company had revenue of $675.29 million for the quarter, compared to analysts' expectations of $678.14 million. Genmab A/S had a net margin of 26.50% and a trailing twelve-month return on equity of 18.06%.

What ETFs hold Genmab A/S's stock?

ETFs with the largest weight of Genmab A/S (NASDAQ:GMAB) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT) , iShares Biotechnology ETF (IBB) , Goldman Sachs Future Health Care Equity ETF (GDOC) and B.A.D. Etf (BAD) . Range Cancer Therapeutics ETF (CNCR) .

What guidance has Genmab A/S issued on next quarter's earnings?

Genmab A/S issued an update on its FY 2024 earnings guidance on Wednesday, February, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.7 billion-$3.0 billion, compared to the consensus revenue estimate of $2.8 billion.

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA) , Alibaba Group (BABA) , Johnson & Johnson (JNJ) , CVS Health (CVS) , Home Depot (HD) , Intel (INTC) , Pfizer (PFE) , PayPal (PYPL) , Verizon Communications (VZ) and Cisco Systems (CSCO) .

When did Genmab A/S IPO?

Genmab A/S (GMAB) raised $503 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

Who are Genmab A/S's major shareholders?

Genmab A/S's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Marotta Asset Management (0.00%), Park Avenue Securities LLC (0.00%) and GAMMA Investing LLC (0.00%).

How do I buy shares of Genmab A/S?

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GMAB

Genmab A/S (GMAB) Stock Price, News & Analysis

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

Free GMAB Stock Alerts

$28.80

-0.71 (-2.41%)

(As of 09:40 AM ET)

Compare

Today's Range: $28.80
▼
$29.07
50-Day Range: $26.43
▼
$31.68
52-Week Range: $26.32
▼
$42.99

Volume: 14,442 shs
Average Volume: 597,782 shs
Market Capitalization: $19.04 billion

P/E Ratio: 30.00
Dividend Yield: N/A
Price Target: $48.50

Get Genmab A/S alerts:

Genmab A/S MarketRank™ Stock Analysis

Analyst Rating: Hold
2.38 Rating Score
Upside/Downside: 64.2% Upside
$48.50 Price Target
Short Interest: Healthy
0.37% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.42
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 35.85%
From $1.06 to $1.44 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.66 out of 5 stars

Medical Sector

258th out of 928 stocks

Pharmaceutical Preparations Industry

113th out of 434 stocks

4.2

Analyst's Opinion

Consensus Rating
Genmab A/S has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 8 buy ratings, 2 hold ratings, and 3 sell ratings.
Amount of Analyst Coverage
Genmab A/S has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
0.37% of the float of Genmab A/S has been sold short.
Short Interest Ratio / Days to Cover
Genmab A/S has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Genmab A/S has recently increased by 17.07%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Genmab A/S does not currently pay a dividend.
Dividend Growth
Genmab A/S does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GMAB.

1.9

News and Social Media Coverage

News Sentiment
Genmab A/S has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Genmab A/S this week, compared to 4 articles on an average week.
Search Interest
Only 2 people have searched for GMAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Genmab A/S insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.54% of the stock of Genmab A/S is held by insiders.
Percentage Held by Institutions
Only 7.07% of the stock of Genmab A/S is held by institutions.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Genmab A/S are expected to grow by 35.85% in the coming year, from $1.06 to $1.44 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Genmab A/S is 30.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.07.
Price to Earnings Ratio vs. Sector
The P/E ratio of Genmab A/S is 30.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 166.67.
Price to Earnings Growth Ratio
Genmab A/S has a PEG Ratio of 2.10. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Genmab A/S has a P/B Ratio of 4.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About Genmab A/S Stock (NASDAQ:GMAB)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

GMAB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GMAB Stock News Headlines

April 16, 2024 | finanznachrichten.de

Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2024

April 16, 2024 | globenewswire.com

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

April 15, 2024 | globenewswire.com

Transactions in Connection with Share Buy-back Program Genmab

April 14, 2024 | americanbankingnews.com

Genmab A/S (NASDAQ:GMAB) Given Average Rating of "Hold" by Brokerages

April 8, 2024 | globenewswire.com

Transactions in Connection with Share Buy-back Program

April 8, 2024 | americanbankingnews.com

FY2025 EPS Estimates for Genmab A/S (NASDAQ:GMAB) Lowered by William Blair

April 6, 2024 | americanbankingnews.com

Q2 2024 Earnings Estimate for Genmab A/S Issued By William Blair (NASDAQ:GMAB)

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

April 5, 2024 | benzinga.com

Genmab Stock (NASDAQ:GMAB), Quotes and News Summary

April 3, 2024 | msn.com

Genmab Buys Ovarian Cancer Drug Developer for $1.8 Billion

April 3, 2024 | bizjournals.com

ProfoundBio to be acquired by Danish biotech giant Genmab for $1.8 billion

April 3, 2024 | msn.com

M&A News: Genmab (NASDAQ:GMAB) Is Acquiring ProfoundBio for $1.8B

April 3, 2024 | finance.yahoo.com

Genmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion Takeover

April 3, 2024 | investopedia.com

Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio

April 3, 2024 | msn.com

Genmab to purchase US-based biotech company ProfoundBio for $1.8 billion in all-cash deal

April 3, 2024 | finance.yahoo.com

Genmab Strengthens Oncology Portfolio With $1.8 Bln Acquisition of ProfoundBio

April 3, 2024 | reuters.com

Denmark's Genmab to acquire ProfoundBio for $1.8 billion

April 3, 2024 | businesswire.com

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

April 3, 2024 | globenewswire.com

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

April 2, 2024 | globenewswire.com

Transactions in Connection with Share Buy-back Program

March 25, 2024 | globenewswire.com

Transactions in Connection with Share Buy-back Program

March 23, 2024 | wsj.com

Genmab A/S ADR

March 18, 2024 | nz.finance.yahoo.com

The 10 best dressed from the 2024 NAACP Image Awards

March 18, 2024 | globenewswire.com

Completion of share buy-back program

March 15, 2024 | ca.finance.yahoo.com

GMAB Apr 2024 30.000 put

March 15, 2024 | msn.com

Biogen chief medical officer departs, joins Alto Neuroscience board

See More Headlines

Receive GMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/14/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GMAB
CUSIP: N/A
CIK: 1434265
Web: www.genmab.com
Phone: (457) 020-2728
Fax: N/A
Employees: 2,204
Year Founded: 1999

Price Target and Rating

Average Stock Price Target: $48.50
High Stock Price Target: $50.00
Low Stock Price Target: $46.00
Potential Upside/Downside: +64.4%
Consensus Rating: Hold
Rating Score (0-4): 2.38
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.96
Trailing P/E Ratio: 30.74
Forward P/E Ratio: 27.84
P/E Growth: 2.1
Net Income: $631.91 million
Net Margins: 26.50%
Pretax Margin: 34.22%
Return on Equity: 18.06%
Return on Assets: 16.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.34
Quick Ratio: 13.32

Sales & Book Value

Annual Sales: $2.39 billion
Price / Sales: 8.16
Cash Flow: $1.25 per share
Price / Cash Flow: 23.60
Book Value: $6.95 per share
Price / Book: 4.25

Miscellaneous

Outstanding Shares: 661,230,000
Free Float: 651,047,000
Market Cap: $19.51 billion
Optionable: Optionable
Beta: 0.98

Social Links

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Jan G.J. van de Winkel Ph.D. (Age 63)
Co-Founder, President & CEO
Comp: $2.9M
Mr. Anthony Pagano (Age 46)
Executive VP & CFO
Comp: $1.03M
Ms. Birgitte Stephensen M.Sc. (Age 63)
Executive VP & Chief Legal Officer
Comp: $638.88k
Dr. Martine J. van Vugt Ph.D. (Age 53)
Executive VP & Chief Strategy Officer
Comp: $696.97k
Mr. Martin Schultz (Age 48)
Senior Director of Clinical Operations & Non-Independent Director
Comp: $116.16k
Dr. Tahamtan Ahmadi (Age 51)
Executive VP, Chief Medical Officer & Head of Experimental Medicines
Comp: $1.12M
Dr. Mijke Zachariasse Ph.D. (Age 50)
Senior Director, Head of Antibody Research Materials & Non-Independent Director
Comp: $159.72k
Mr. Takahiro Hamatani (Age 49)
Senior Director of Finance Japan & Non-Independent Director
Comp: $116.16k
Mr. Anthony Mancini (Age 53)
Executive VP & COO
Comp: $1.1M
Mr. Andrew Carlsen
Senior Director, VP & Head of Investor Relations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Genmab A/S:

Genmab A/S has a strong pipeline of innovative monoclonal antibody-based products, including the latest versions like tisotumab vedotin, which shows promising results in clinical trials for various cancer indications.
The company has successful collaborations with major pharmaceutical companies like Novartis and Johnson & Johnson, providing opportunities for revenue growth and product development.
Genmab A/S has a solid financial position with steady revenue growth and a healthy balance sheet, making it a stable investment option in the biopharmaceutical industry.
The stock price of Genmab A/S has shown consistent growth over the past year, reflecting positive investor sentiment and potential for further appreciation.
With a focus on cutting-edge technologies and research, Genmab A/S is well-positioned to capitalize on the growing demand for targeted cancer therapies, offering long-term growth prospects for investors.

Cons

Investors should be bearish about investing in Genmab A/S for these reasons:

Genmab A/S faces intense competition in the biopharmaceutical industry, which may impact market share and pricing strategies for its products.
Regulatory challenges and uncertainties in drug approvals could lead to delays in product commercialization, affecting revenue projections and investor confidence.
The biopharmaceutical sector is inherently risky due to the high costs of research and development, potential clinical trial failures, and market volatility, posing risks to investor returns.
Fluctuations in exchange rates and global economic conditions may impact Genmab A/S's international operations and financial performance, introducing currency and geopolitical risks for investors.
Investing in biopharmaceutical companies like Genmab A/S requires a thorough understanding of complex scientific and regulatory processes, which may pose challenges for investors without specialized knowledge in the field.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com.

GMAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Genmab A/S stock right now?: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 3 sell ratings, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
View GMAB analyst ratings or view top-rated stocks.
What is Genmab A/S's stock price target for 2024?: 13 brokerages have issued 12 month price targets for Genmab A/S's stock. Their GMAB share price targets range from $46.00 to $50.00. On average, they anticipate the company's share price to reach $48.50 in the next twelve months. This suggests a possible upside of 64.2% from the stock's current price.
View analysts price targets for GMAB or view top-rated stocks among Wall Street analysts.
How have GMAB shares performed in 2024?: Genmab A/S's stock was trading at $31.84 at the beginning of 2024. Since then, GMAB stock has decreased by 7.2% and is now trading at $29.54.
View the best growth stocks for 2024 here.
Are investors shorting Genmab A/S?: Genmab A/S saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,400,000 shares, an increase of 17.1% from the March 15th total of 2,050,000 shares. Based on an average daily volume of 626,600 shares, the short-interest ratio is currently 3.8 days. Approximately 0.4% of the company's stock are short sold.
View Genmab A/S's Short Interest.
When is Genmab A/S's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our GMAB earnings forecast.
How were Genmab A/S's earnings last quarter?: Genmab A/S (NASDAQ:GMAB) issued its quarterly earnings data on Wednesday, February, 14th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.02. The company had revenue of $675.29 million for the quarter, compared to analysts' expectations of $678.14 million. Genmab A/S had a net margin of 26.50% and a trailing twelve-month return on equity of 18.06%.

What ETFs hold Genmab A/S's stock?: ETFs with the largest weight of Genmab A/S (NASDAQ:GMAB) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), Goldman Sachs Future Health Care Equity ETF (GDOC) and B.A.D. Etf (BAD).Range Cancer Therapeutics ETF (CNCR).
What guidance has Genmab A/S issued on next quarter's earnings?: Genmab A/S issued an update on its FY 2024 earnings guidance on Wednesday, February, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.7 billion-$3.0 billion, compared to the consensus revenue estimate of $2.8 billion.
What other stocks do shareholders of Genmab A/S own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO).
When did Genmab A/S IPO?: Genmab A/S (GMAB) raised $503 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.
Who are Genmab A/S's major shareholders?: Genmab A/S's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Marotta Asset Management (0.00%), Park Avenue Securities LLC (0.00%) and GAMMA Investing LLC (0.00%).
How do I buy shares of Genmab A/S?: Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GMAB) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Genmab A/S (GMAB) Stock Price, News & Analysis

Genmab A/S MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Genmab A/S Stock (NASDAQ:GMAB)

GMAB Stock Price History

GMAB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

Pros

Cons

GMAB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™